Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach
- 8 June 2011
- journal article
- review article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 52 (8), 1425-1434
- https://doi.org/10.3109/10428194.2011.568654
Abstract
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) is usually an incidental diagnosis in patients with early–intermediate stage disease. However, most patients with a diagnosis of CLL will subsequently have significant morbidity and die from their disease and its complications. For these patients, CLL is not the ‘good leukemia’ with a predictably ‘benign’ outcome. Indeed, we can now identify a cohort of patients with high-risk CLL at diagnosis who will have rapid disease progression, poor response to treatment, and poor survival based on prognostic methods developed from an improved understanding of the biology of CLL. The concomitant development of improved treatments has led to risk-adjusted management approaches that could improve outcomes. We discuss the clinical and laboratory components of comprehensive risk evaluation of patients with CLL and our approach to the management of patients with a high to very high risk of disease progression and poor outcome. In addition, we review the challenges and prospects for improving prognostic precision and the development of new drugs to improve the treatment of patients with CLL with a high risk of adverse outcome.Keywords
This publication has 68 references indexed in Scilit:
- CD5-positive chronic B-cell lymphoproliferative disorders: Diagnosis and prognosis of a heterogeneous disease entityCytometry Part B: Clinical Cytometry, 2010
- Pentostatin and rituximab therapy for previously untreated patients with B‐cell chronic lymphocytic leukemiaCancer, 2010
- Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisoneLeukemia & Lymphoma, 2010
- Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative ConditioningJournal of Clinical Oncology, 2008
- Early treatment of high‐risk chronic lymphocytic leukemia with alemtuzumab and rituximabCancer, 2008
- Genomic complexity identifies patients with aggressive chronic lymphocytic leukemiaBlood, 2008
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drugJCI Insight, 2008
- The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphomaBritish Journal of Haematology, 2008
- Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaBlood, 2006